Clinical trials: Moderate to Severe Dry Eye
Dry Eye Syndrome
A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye
The objective of this study is to assess the efficacy and safety of rhNGF eye drops at 20 μg/ml concentration administered two or three times daily for 4 weeks in patients with moderate to severe dry eye.
- Trial name
- NCT03982368
- Testing
- rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle
- Where
- 12 sites in United States
- Volunteers
- 261 people
- Sponsor
- Dompé Farmaceutici S.p.A
Dry Eye Disease (DED)
Evaluate the Efficacy and Safety of Amnion Membrane Disc Allograft vs Standard of Care in Participants With Dry Eye Disease
To evaluate the efficacy of Lyophilized Human Amnion Membrane Disc in reducing corneal epithelial damage as measured by the Lexitas Modified National Eye Institute (NEI) Grading Scale for Corneal Fluorescein Staining.
- Trial name
- BLINK (NCT07529899)
- Testing
- Standard of Care (SOC), Lyophilized Amnion Membrane Disc Allograft
- Sponsor
- Cellution Biologics
Dry Eye Disease (DED)
Moderate-to-Severe Dry Eye Disease Relief Using Acoltremon
To evaluate the impact of Acoltremon 0.003% on subjective dry eye symptoms using validated patient-reported outcome measures: Eye Dryness Score Visual Analog Scale (EDS-VAS).
- Trial name
- ASTRA (NCT07268599)
- Testing
- Acoltremon
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Colvard Kandavel Eye Center
Moderate to Severe Dry Eye
A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease
This study is a multicenter, randomized, double-blind, placebo-controlled, superiority design Phase III clinical trial. The primary objective is to evaluate the efficacy and safety of cyclosporine ophthalmic gel versus placebo in…
- Trial name
- NCT06766357
- Testing
- Cyclosporine ophthalmic gel, Cyclosporine ophthalmic gel vehicle
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Dry Eye Syndromes, Dry Eye Disease (DED)
Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED
The goal of this clinical investigation plan is to evaluate the performance, tolerability, safety, and compliance of an ophthalmic solution containing an ancillary medicinal substance and hyaluronic acid 0.3% (FBV_01) compared…
- Trial name
- NCT07412860
- Testing
- FBV_01, HYLO-VISION® SafeDrop® Gel
- Where
- 2 sites in Italy
- Volunteers
- 74 people
- Sponsor
- FB Vision S.p.A
Dry Eye Disease
Safety and Efficacy of Two Different Concentrations (0.5% and 1%) of Progesterone Topical Gel Compared to Placebo in Patients Diagnosed With Moderate to Severe Dry Eye Syndrome
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Phase 2 clinical trial. The study objective is to evaluate the safety and efficacy of two different concentrations (0.5% and 1%) of progesterone topical…
- Trial name
- ProGIFT (NCT04645446)
- Testing
- Pro-ocular gel
- Where
- 4 sites in Italy
- Volunteers
- 96 people
- Sponsor
- SIFI SpA
Dry Eye
Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes
To compare the efficacy, safety and tolerability of 0.05% topical cyclosporin eye drop to Refresh in moderate to severe dry eye patients. Null hypothesis is: there is no difference between these two groups.
- Trial name
- NCT00704275
- Testing
- 0.05% cyclosporin eye drop
- Where
- 2 sites in Thailand
- Volunteers
- 60 people
- Sponsor
- Chulalongkorn University
Dry Eye Syndrome (DES)
Evaluation of Performance and Safety of Eye Drops With Hyaluronic Acid 0.30% and 0.15%
This is a profit, multicentric, prospective, open-label, non-pharmacological clinical investigation aim to evaluate the efficacy and tollerability of two types of eye drops containing Hyaluronic acid (HA) with different…
- Trial name
- NCT06189456
- Testing
- BLUgel A, BLUyal A
- Where
- 3 sites in Italy
- Volunteers
- 101 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Primary Sjögren's Syndrome (pSS)
Exploratory Study on the Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Moderate to Severe Primary Sjögren's Syndrome
The goal of this clinical trial is to learn if blinatumomab works to treat moderate-to-severe primary Sjögren's Syndrome. It will also learn about the safety of low-dose blinatumomab.
- Trial name
- NCT07852234
- Testing
- Blinatumomab, background treatment
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tongren Hospital
Sjogren's Syndrome (SS)
An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) in Adult Participants With Moderately to Severely Active Primary Sjogren's Syndrome (pSS)
Sjogren's syndrome (SS) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary gland inflammation, with resultant dryness of the eyes and mouth and occasional glandular enlargement.
- Trial name
- NCT05217472
- Testing
- Ravaglimab, Ravagalimab
- Where
- Netherlands
- Sponsor
- AbbVie
Dry Eye Syndrome
Systane Clinical Experience Study
To evaluate the physical effect of SYSTANE QID in people that have moderate to severe dry eyes and to establish doctor confidence to prescribe Systane.
- Trial name
- NCT00818909
- Testing
- Systane
- Volunteers
- 941 people
- Sponsor
- Alcon Research